Dawson James analyst Jason Kolbert reiterated a Buy rating on Athersys (NASDAQ:ATHX) on Tuesday, setting a price target of $12, which is approximately 358.02% above the present share price of $2.62.
Kolbert expects Athersys to post earnings per share (EPS) of -$0.06 for the second quarter of 2020.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in Athersys, with an average price target of $9.
The analysts price targets range from a high of $12 to a low of $6.
In its latest earnings report, released on 12/31/2019, the company reported a quarterly revenue of $287.00 thousand thousand and a net profit of -$9.99 million. The company's market cap is $501.01 million.
According to TipRanks.com, Dawson James analyst Jason Kolbert has 0 stars on 0-5 stars ranking scale with an average return of -8.7% and a 35.8% success rate.
Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.